NCT00338260

Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954-133)

A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 496 (actual)
• Sponsor: Organon and Co · Industry
• Sex: All
• Age: 55 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The LIFE study was conducted from 1995-2001. This study was conducted in 9193 patients with high blood pressure and thickening of the main pumping chamber of the heart. The results showed that after an average treatment time of 4.8 years, treatment that was based on losartan was better than treatment based on atenolol for reducing the risk of having a stroke. The main study results were published in Dahlof et al. Lancet 2002;359:995-1003.

Conditions

• Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart)

Interventions

Type	Name	Description
DRUG	MK0954, /Duration of Treatment : 5 Years
DRUG	Comparator : atenolol /Duration of Treatment : 5 Years

Timeline

• Start date: 1995-06-01
• Primary completion: 2001-09-01
• Completion: 2001-11-01
• First posted: 2006-06-20
• Last updated: 2022-02-15